EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats

Wenbin Zhang,Ajith A. Welihinda,Jordan A. Mechanic,Haifeng Ding,Liangcheng Zhu,Yuan Lu,Zhongping Deng,Zelin Sheng,Binhua Lv,Yuanwei Chen,Jacques Y. Roberge,Brian Seed,Yong-Xiang Wang

DOI: https://doi.org/10.1016/j.phrs.2011.01.001

IF: 10.334

2011-01-01

Pharmacological Research

Abstract:Sodium glucose co-transporter 2 (SGLT2) is a renal type III integral membrane protein that co-transports sodium and glucose from filtrate to epithelium in the proximal tubule. Human subjects with homozygous or compound heterozygous mutations in SLC5A2 exhibit glucosuria without hypoglycemia or other obvious morbidity, suggesting that blockade of SGLT2 has the potential to promote normalization of blood glucose without hypoglycemia in the setting of type 2 diabetes. This report presents the in vitro and in vivo pharmacological activities of EGT1442, a recently discovered SGLT2 inhibitor in the C-aryl glucoside class.